SEOUL, South Korea, Jan. 20, 2026 /PRNewswire/ -- Digital healthcare startup 6Letters today announced the official launch of MOJO KING, an iOS application that enables non-invasive monitoring of testosterone-related physiological patterns using Apple Watch data.
MOJO KING leverages heart rate variability (HRV)—a standard biometric signal collected by Apple Watch—to analyze changes associated with male hormonal balance. Without requiring blood tests or external sensors, the app allows users to track hormone-related trends seamlessly in everyday life.
The current version of MOJO KING analyzes individual biometric signals in relation to age-group baselines and 24-hour circadian rhythms. Based on this analysis, users are classified into intuitive categories: "Teto Guy" when values are above the age-adjusted average, or "Egen Guy" when below. Results are presented in a user-friendly visual format and can be easily shared via social media platforms such as Instagram.
With a paid subscription, users can remove in-app advertisements and enable automatic, continuous measurements, allowing them to observe personalized hormone-related changes over time. This supports a shift from one-time readings to longitudinal, trend-based hormone monitoring tailored to individual lifestyles.
MOJO KING is built on a foundation of multiple patents and peer-reviewed scientific research. To further enhance accuracy and personalization, 6Letters is currently training machine-learning models using large-scale medical datasets from the UK Biobank, CDC, Physionet etc. Insights derived from this work will power the next generation of the company's hormone analytics platform.
Notably, MOJO KING goes beyond conventional smartwatch fitness use cases that focus primarily on heart rate and respiration during aerobic exercise. The app introduces a differentiated approach by analyzing pre- and post-changes associated with moderate-to-high-intensity resistance training, offering new insights into hormone-related responses to strength-focused workouts.
Looking ahead, 6Letters plans to expand MOJO KING with additional modes, including hormone-dependent hair loss management and growth-phase optimization. The company is also preparing to launch MOJO QUEEN, a complementary digital health application focused on female hormone analytics.
In parallel, 6Letters is currently conducting a pre-seed funding round at an approximate company valuation of USD 5 million. The company expects to complete AI training based on a huge medical data and plans to apply for FDA 510(k) clearance in the first half of 2026, followed by entry into the U.S. Remote Patient Monitoring (RPM) reimbursement market.
MOJO KING is designed to help users understand and manage hormone-related physiological signals in everyday life, said a representative of 6Letters. By combining scientific evidence, large-scale medical data, and wearable technology, 6Letters aims to build a globally scalable digital hormone health platform.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
6Letters Launches "MOJO KING," an Apple Watch-Based iOS App for Non-Invasive Testosterone Monitoring
Mass General Brigham Department of Radiology Begins Clinical Validation and Utility of Three MediAI Pediatric Solutions
BOSTON and SEOUL, South Korea, June 16, 2026 /PRNewswire/ -- Crescom (CEO Jae Joon Lee), a medical AI company specializing in musculoskeletal analysis, has officially launched a global clinical PoC of its pediatric musculoskeletal AI solutions in collaboration with the Department of Radiology at Mass General Brigham. Mass General Brigham (MGB) is one of the largest academic healthcare systems in the United States. Its premier flagship hospitals, Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH), achieved the number one and number two global rankings, respectively, in the healthcare institution sector of the prestigious Nature Index for research capacity. This upcoming global clinical validation study will be directly conducted by the Department of Radiology at Massachusetts General Hospital (MGH). The collaboration carries significant weight, as Crescom's technology is now undergoing global clinical validation and utility studies at one of the world's foremost institutions in medical imaging.
The validation study covers three core solutions: • bone age analysis AI MediAI-BA (FDA 510(k) cleared) • full lower-limb length measurement AI MediAI-SG • scoliosis severity auto-measurement AI MediAI-SC. Mass General Brigham radiologists will compare AI-generated readings against expert clinical interpretations, conducting a comprehensive assessment of both clinical validity and real-world usability, while collecting user feedback from the U.S. clinical environment to refine the solutions and establish a foundation for local commercialization.
The global healthcare industry, particularly in the United States, is currently facing severe physician burnout and diagnostic bottlenecks driven by a surge in medical imaging demand and a critical shortage of specialized radiologists. While the number of pediatric imaging specialists remains extremely limited, the volume of related imaging studies continues to grow steadily. Consequently, clinical fields are showing rapidly increasing interest in optimizing operational workflows through AI-driven automated analysis. Through this clinical validation study with Mass General Brigham, Crescom plans to objectively demonstrate, utilizing data from a world-renowned institution, that its musculoskeletal AI technology can substantively improve the reading efficiency of medical specialists.
This collaboration with Mass General Brigham is expected to serve as a pivotal milestone for Crescom to establish a robust clinical track record in the North American radiology and pediatric growth clinic markets, while expanding its network with key local healthcare institutions. Furthermore, the company plans to pioneer high-value business domains by integrating its pediatric musculoskeletal analysis and growth prediction solutions with the North American youth athletic development industry, where substantial potential demand is anticipated.
"Building on the upcoming results of this validation, we will aggressively expand our footprint across the North American market," said Jae Joon Lee, CEO of Crescom.
The study is also supported by the Ministry of Health and Welfare of the Republic of Korea.
About Crescom: Crescom is a medical AI company specializing in musculoskeletal analysis solutions. The company develops and provides Onzaram, a pediatric growth management app, and the MediAI series of AI-powered medical imaging analysis solutions. MediAI-BA has received domestic regulatory approval in Korea and has obtained FDA 510(k) clearance in the United States, as well as regulatory approvals in Thailand and Malaysia, providing bone age analysis services to medical institutions worldwide. (www.crescom.ai)
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Crescom Launches Global PoC of Pediatric Musculoskeletal AI with Mass General Brigham
